Publications on sustained-release
Impact of Granulation Solvent on Release Performance of Dual Matrix Extended Release Tablets of Highly Water Soluble Drugs Formulated using Compritol® 888 ATO and Methocel® as Release Retarding Agents
Ketkee Deshmukh, Swarnadeep Banerjee, Agnivesh Shrivastava, Sunil Bambarkar
The purpose of this study is to evaluate the impact of different granulation solvents on the performance of dual extended- release matrix tablets, formulated using a combination of Compritol® 888 ATO and Methocel® K100M, with two model APIs:
- highly water-soluble high dose (1000 mg) Metformin Hydrochloride
- freely water-soluble low dose (95 mg) Metoprolol Succinate
Oral Drug Delivery for Modified Release Formulations
Edmund S. Kostewicz, Maria Vertzoni, Heather A. E. Benson, Michael S. Roberts
Wiley Library, April 2022
Selecting efficient pharmaceutical binder for developing robust extended-release matrices of Compritol® 888 ATO prepared using wet granulation technique : Part 1 Studying impact on granule & tablet properties
K. Deshmukh, A. Shrivastava, S. Banerjee, R. Tiwari, S. Bambarkar, N. Farah Gattefosse India Pvt. Ltd., Mumbai, INDIA, Gattefosse SAS, Lyon, FRANCE
CRS 2021
Selecting efficient pharmaceutical binder for developing robust extended-release matrices of Compritol® 888 ATO prepared using wet granulation technique: Part 2 Studying impact on dissolution profiles of ER tablets of different API’s
K. Deshmukh1, A. Shrivastava1, S. Banerjee1, R. Tiwari1, S. Bambarkar1, N. Farah2 1Gattefosse India Pvt. Ltd., Mumbai, INDIA, 2Gattefosse SAS, Lyon, FRANCE
CRS 2021
Evolution of the Microstructure of Sustained-release Matrix Tablets during Dissolution and Storage
V. JANNIN, E. LECCIA, Y. ROSIAUX AND J. DOUCET
Indian J Pharm Sci 2018;80(6):1011-1020
QbD – How particle size and glyceride composition affect the performance of sustained-release tablets with Compritol 888 ATO
Yvonne Rosiaux, Amandine Forrest, Jean-Michel Girard, Carole Deleglise, Delphine Marchaud
Compritol® 888 ATO: a sustained release lipid matrix for once a day aceclofenac tablets
C. J. Kapadia, A. R. Shrivastava, G. R. Khanvilkar AAPS 2016
Influence of Formulation Factors and Compression Force on Release Profile of Sustained Release Metoprolol Tablets using Compritol® 888 ATO as Lipid Excipient
Shilpa N. PATERE, Chhanda J. KAPADIA and Mangal S. NAGARSENKER Indian J Pharm Sci 2015;77(5): 620-625 Release profile of metoprolol from sustained release tablets using Compritol 888 ATO as SR lipid matrix agent showed high reliability. Different sources of active ingredient and batches of Compritol were evaluated at different compression forces and in dissolution media containing or not ethanol. The formulation appeared to be very robust and is not affected by these variables. Therefore Compritol offers great potential in the formulation of reliable SR tablets.
New insights into the stability of SR lipid matrix tablets
Y. Rosiaux, V. Jannin, J. Doucet*, J-M. Girard, F. Desvignes, and D. Marchaud CRS 2015
Effect of Tablet Structure on Controlled Release from Supersaturating Solid Dispersions Containing Glyceryl Behenate.
Justin M. Keen, Justin R. Hughey, Ryan C. Bennett, Vincent Jannin, Yvonne Rosiaux, Delphine Marchaud, and James W. McGinity
Smart strategies for sustained release tablets: Compritol® 888 ATO
White paper – May 2014 This white paper gives an overview of how Compritol® 888 ATO provides clinically relevant sustained drug release profiles along with biopharmaceutical, formulation and manufacturing advantages.
Solid lipid excipients – matrix agents for sustained drug delivery.
Yvonne Rosiaux, Vincent Jannin, Sophie Hughes, Delphine Marchaud Journal of Controlled Release Volume 188, 28 August 2014, Pages 18–30
This review article focuses on the utility of lipid excipients in solid sustained drug delivery systems with emphasis on the efficiency and robustness of these systems with respect to: (i) the choice of the manufacturing process and impact on drug release, (ii) the fundamental drug release mechanisms, (iii) resistance of the drug formulation under physiological conditions and (iv) long-term stability. Understanding the functionality of these versatile excipients in formulation is elementary for the development of highly robust lipid-based sustained release medicines
Sustained release levadopa mini-tablets containing Compritol® 888: a viable approach for special patient populations
AAPS 2013
Compritol®888 ATO a lipid excipient for sustained release of highly water soluble active: formulation, scale-up and IVIVC study.
Patere SN, Desai NS, Jain AS, Kadam PP, Thatte UM, Gogtay N, Kapadia CJ, Farah N, Nagarsenker MS.
Curr Drug Deliv. 2013 Oct;10(5):548-56.
Ethanol resistant extended release matrix tablets with Compritol® 888 ATO
Poster AAPS 2014
Estimating in vivo drug release from a new theophylline Compritol® 888 ATO matrix formulation using appropriate biorelevant test methods
Poster CRS 2014
Streamlining the design of sustained release matrix tablets using mathematical modeling for drug release optimization
Poster CRS 2014
The effect of process on drug release of Compritol® 888 sustained release tablets: direct compression, wet granulation and hot melt extrusion
Poster CRS 2014
Formulation Effects on Drug Release from Sustained-Release Compritol® 888 ATO Tablets and Mini-Tablets
CRS 2011
